Navigation Links
Rich Countries Need to Curb Genital Surgery Before Criticizing Traditional Practices

Female genital mutilation (FGM), excision of clitoris is practiced as an initiation rite for women in rich countries without the use of anesthetics. A senior doctor sounds// off that instead of blaming the traditional practice that is going on for generations, sorting out the aesthetic procedure seeks prime importance.

A report published on bmj.com last month probes that the procedure of mutilation performed among girls and women in Sudan did not actually appear in the World Health Organisation’s classification system.

The literature on female genital mutilation is long on polemic and short on data, he writes. European and American writers often assume that female genital mutilation is forced on unwilling young girls, but this is at odds with the high social value placed on it in societies that practise it.

The high moral tone with which those in richer countries criticise female genital mutilation would also be more credible if we in the rich North had not practised it and did not continue to practise it, he adds.

The practice of female genital mutilation is on the increase nowhere in the world except our so called developed societies, he says. "Designer laser vaginoplasty" and "laser vaginal rejuvenation" are growth areas in plastic surgery, representing the latest chapter in the surgical victimisation of women in our culture.

And this burgeoning industry is able to operate without the slightest attention being paid to it by medical researchers.

It is Western medicine which, by a process of disease mongering, is driving the advance of female genital mutilation by promoting the fear in women that what is a natural biological variation is a defect, a problem requiring a knife, he concludes.

(Source: Eurekalert)
'"/>




Page: 1

Related medicine news :

1. Lung Cancer Deaths Declining In Men But Not Women In European Countries
2. HIV Infection Higher In Drug Trafficking Countries
3. European Countries To Fund $4 Billion For Vaccination For Poor Children’
4. Bird Flu Meet called by France for EU Countries
5. Pak Ban On Poultry Imports From 17 Countries
6. More Funds required for Asian Countries to fight Bird Flu
7. Record Number of Countries Contributed to UNFPA in 2005
8. Countries Step up Battle Against Bird Flu
9. Home Based HIV counseling in African Countries
10. Need For Low Cost, Heat Stable HIV Drug in Developing Countries
11. Poultry Sales In EU Countries Show Recovery
Post Your Comments:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10